Residency · Residency · Ophthalmology
Immunomodulatory Therapy for Uveitis
Introduction
Immunomodulatory therapy (IMT) is the cornerstone of management for chronic, recurrent, or sight-threatening non-infectious uveitis. The goal is to achieve durable disease quiescence while minimizing corticosteroid-related adverse effects. Selection of the appropriate agent requires an understanding of mechanism of action, efficacy data, monitoring requirements, and patient-specific factors.
Indications for Immunomodulatory Therapy
Steroid dependence: inability to taper below a prednisone equivalent of 7.5 mg/day within 3 months. Steroid intolerance: unacceptable side effects (glucose intolerance, osteoporosis, weight gain, psychosis) Sight-threatening disease: Behcet disease, VKH, sympathetic ophthalmia, severe intermediate or posterior uveitis. Bilateral chronic uveitis with risk of cumulative steroid toxicity. Recurrent disease requiring repeated corticosteroid rescue.
General Principles
Bridge with corticosteroids while waiting for IMT to take effect (onset typically 4-12 weeks) Monotherapy is preferred; combination therapy is reserved for refractory cases. Regular laboratory monitoring (CBC, hepatic function, renal function) is mandatory. Pregnancy considerations: methotrexate and mycophenolate are teratogenic; coordinate with the patient's obstetrician. Treat-to-target: aim for complete quiescence (no cells, no macular edema) on no or minimal corticosteroids.
Antimetabolites
Methotrexate (MTX)
Mechanism: dihydrofolate reductase inhibitor; inhibits purine and pyrimidine synthesis. Dose: 15-25 mg weekly (oral or subcutaneous); supplement with folic acid 1 mg daily. Onset: 4-8 weeks. Efficacy: effective for anterior, intermediate, and posterior uveitis; scleritis. Monitoring: CBC and LFTs every 4-8 weeks; chest X-ray at baseline. Side effects: hepatotoxicity, cytopenias, mucositis, pneumonitis.
Contraindication: pregnancy (Category X), significant liver disease, immunodeficiency.
Mycophenolate Mofetil (MMF)
Mechanism: inosine monophosphate dehydrogenase inhibitor; selectively targets lymphocyte proliferation. Dose: 1-1.5 g twice daily. Onset: 6-12 weeks. Well tolerated; main side effects are GI disturbance and cytopenias. Preferred in patients who cannot tolerate methotrexate.
Azathioprine
Mechanism: purine analogue; inhibits DNA synthesis in rapidly dividing cells. Dose: 1-3 mg/kg/day. Check thiopurine methyltransferase (TPMT) activity before starting; deficiency increases risk of severe myelosuppression. Generally considered less effective than MTX or MMF; used when others are contraindicated.
Immunomodulatory Agents Summary
| Agent | Class | Mechanism | Dose | Onset | Key Monitoring | Key Side Effects | Pregnancy |
|---|---|---|---|---|---|---|---|
| Methotrexate | Antimetabolite | DHFR inhibitor | 15-25 mg/wk | 4-8 wk | CBC, LFTs q4-8wk | Hepatotoxicity, cytopenias, pneumonitis | Category X |
| Mycophenolate | Antimetabolite | IMPDH inhibitor | 1-1.5 g BID | 6-12 wk | CBC, LFTs | GI disturbance, cytopenias | Category X |
| Azathioprine | Antimetabolite | Purine analogue | 1-3 mg/kg/day | 6-12 wk | TPMT level, CBC, LFTs | Myelosuppression, pancreatitis | Safer (Category D) |
| Cyclosporine | Calcineurin inhibitor | Blocks IL-2/T-cells | 2-5 mg/kg/day | 4-6 wk | BP, creatinine, drug level | Nephrotoxicity, HTN | Category C |
| Adalimumab | Biologic (anti-TNF) | TNF-alpha inhibitor | 40 mg q2wk SC | 4-8 wk | TB screen, hepatitis panel | Infection, demyelination, lymphoma | Category B |
| Infliximab | Biologic (anti-TNF) | TNF-alpha inhibitor | 5 mg/kg IV q4-8wk | 2-4 wk | TB screen, hepatitis panel | Infusion reactions, infection | Category B |
| Rituximab | Biologic (anti-CD20) | B-cell depletion | 1g IV x2 | 4-8 wk | Immunoglobulins, B-cell count | Infusion reaction, PML (rare) | Category C |
| Tocilizumab | Biologic (anti-IL-6) | IL-6R antagonist | 4-8 mg/kg IV or SC | 4-8 wk | CBC, LFTs, lipids | Infection, neutropenia, GI perforation | Category C |
Calcineurin Inhibitors
Cyclosporine A
Mechanism: inhibits calcineurin, blocking IL-2 transcription and T-cell activation. Dose: 2-5 mg/kg/day in divided doses. Effective for Behcet disease, VKH, birdshot chorioretinopathy. Monitoring: blood pressure, renal function (creatinine), trough drug levels. Side effects: nephrotoxicity, hypertension, hirsutism, gingival hyperplasia.
Tacrolimus
10-100 times more potent than cyclosporine at equivalent doses. Similar mechanism but different binding protein (FKBP-12 vs. cyclophilin) Lower incidence of cosmetic side effects; nephrotoxicity remains a concern.
Biologic Agents
Adalimumab (Humira)
Anti-TNF-alpha monoclonal antibody; FDA-approved for non-infectious intermediate, posterior, and panuveitis. Dose: 40 mg subcutaneously every 2 weeks (80 mg loading dose) VISUAL I and VISUAL II trials demonstrated significant reduction in uveitis flare risk. Screen for latent tuberculosis and hepatitis B before initiation. Side effects: injection site reactions, increased infection risk, rare demyelination, lupus-like syndrome.
Infliximab
Chimeric anti-TNF-alpha monoclonal antibody; intravenous infusion. Dose: 5-10 mg/kg at weeks 0, 2, 6, then every 4-8 weeks. Particularly effective for Behcet disease with ocular involvement. Risk of infusion reactions; anti-drug antibody formation (consider concomitant MTX)
Other Biologics
Tocilizumab (anti-IL-6): emerging evidence for refractory macular edema in uveitis. Rituximab (anti-CD20): used in refractory scleritis and orbital inflammation. Secukinumab (anti-IL-17): studied in uveitis but showed mixed results. Abatacept (CTLA-4-Ig): case series in JIA-associated uveitis.
Alkylating Agents
Cyclophosphamide
Reserved for severe, refractory, or life-threatening disease (e.g., necrotizing scleritis with systemic vasculitis) Dose: oral 1-2 mg/kg/day or IV pulse 750-1000 mg/m2 monthly. Serious side effects: hemorrhagic cystitis, bone marrow suppression, infertility, secondary malignancy. Limit cumulative dose; transition to a safer agent once remission is achieved.
Chlorambucil
Rarely used today due to high toxicity profile. Historical use in Behcet disease before biologic era.
Local Corticosteroid-Sparing Options
Intravitreal Dexamethasone Implant (Ozurdex)
Biodegradable implant releasing dexamethasone over 4-6 months. Useful adjunct for unilateral disease or as a bridge to systemic IMT. Risk of cataract and IOP elevation.
Fluocinolone Acetonide Implant (Retisert / Yutiq)
Long-acting intravitreal implant (Retisert: 30 months; Yutiq: 36 months) High rates of cataract surgery and glaucoma intervention with Retisert. Yutiq has a lower steroid burden and reduced (but still present) IOP risk.
Monitoring and Follow-Up
Baseline labs before starting any IMT: CBC, CMP, hepatitis B/C serologies, TB screening, chest X-ray. Ongoing monitoring schedule varies by agent (see individual drug sections) Ophthalmic follow-up every 4-8 weeks during active treatment; assess for inflammation, macular edema, IOP. Attempt slow corticosteroid taper once IMT reaches therapeutic effect. Duration of therapy: minimum 2 years of quiescence before considering taper of IMT.
Key Clinical Pearls
The goal of IMT is complete inflammatory quiescence on prednisone less than or equal to 7.5 mg/day (or off steroids entirely). Adalimumab is the only FDA-approved biologic for non-infectious uveitis and should be considered early in the treatment algorithm for sight-threatening disease. Always screen for latent tuberculosis and hepatitis B before starting anti-TNF therapy. Coordination with a rheumatologist or internist experienced in IMT enhances patient safety and compliance.
References
- Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders. Am J Ophthalmol. 2000;130(4):492-513.
- Jaffe GJ, Dick AD, Brezin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375(10):932-943.
- Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare (VISUAL II). Lancet. 2016;388(10050):1183-1192.
- Dick AD, Rosenbaum JT, Al-Dhibi HA, et al. Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis. Ophthalmology. 2018;125(5):757-773.